amg510什么意思

药直供官方

药直供官方账号

摘要：AMG 510, also known as Sotorasib, is a new drug that has generated a lot of buzz among cancer researchers and oncologists. Developed by Amgen, AMG 510 is a small-molecule inhibitor that block the acti

有用 0

浏览 235次

2023-03-28 16:55:44 发布

AMG 510, also known as Sotorasib, is a new drug that has generated a lot of buzz among cancer researchers and oncologists. Developed by Amgen, AMG 510 is a small-molecule inhibitor that block the activity of KRAS G12C, a common cancer-causing mutation in many human cancers.

KRAS G12C is a specific mutation in the KRAS gene that is found in about 13% of non-small cell lung cancers, 3-5% of colorectal cancers, and various other cancers such as pancreatic, endometrial, and thyroid cancers. KRAS is a molecular switch that helps to control cell growth and division, and when mutations occur in this gene, it can lead to uncontrolled cell growth and the development of cancer.

The development of AMG 510 is significant because KRAS mutations have long been considered “undruggable” targets. This means that traditional drug development strategies have struggled to find effective drugs that can specifically target and inhibit KRAS activity. With the development of AMG 510, cancer researchers now have a promising drug candidate that could potentially revolutionize cancer treatment.

The early results from clinical trials of AMG 510 have been very promising, with some patients showing dramatic and sustained responses. In a phase 1 study of 129 patients with KRAS G12C-mutant solid tumors, AMG 510 showed encouraging results with a 50% objective response rate and a median progression-free survival of 6.3 months. Importantly, the drug has also been well-tolerated, with only mild side effects reported.

While it is still early days for AMG 510, there is a growing sense of optimism that this drug could be a game-changer in the fight against cancer. If AMG 510 proves to be effective in larger clinical trials and gains approval from regulatory authorities, it could become a new standard of care for patients with KRAS G12C-mutant cancers. Furthermore, the development of AMG 510 has paved the way for the development of other drugs that target other KRAS mutations, offering hope to patients with other types of cancer and their families.

In conclusion, AMG 510, also known as Sotorasib, is a promising new drug that has the potential to significantly improve the treatment of cancer. By targeting KRAS G12C, a common cancer-causing mutation, AMG 510 could offer new hope to patients who were previously considered to have few treatment options. While more research is needed to fully understand the potential of AMG 510, early results suggest that it could be a game-changer in the fight against cancer.

AMG510的相关介绍

肺癌

说明书

注：本站所有内容仅供参考，不代表药直供立场(如有错漏，请帮忙指正)，转载请注明出处。不作为诊断及治疗依据，不可替代专业医师诊断、不可替代医师处方。本站不承担由此导致的相关责任！

2023-03-28 16:55:44 更新

索托拉西布AMG510基本信息
索托拉西布AMG510
- 剂型：
  片剂
- 厂家：
  老挝第二制药
- 适应症：
  KRAS抑制剂，肺癌新特药
索托拉西布AMG510基本信息
索托拉西布AMG510
- 剂型：
  片剂
- 厂家：
  美国安进
- 适应症：
  KRAS抑制剂，肺癌新特药
索托拉西布AMG510基本信息
索托拉西布AMG510
- 剂型：
  片剂
- 厂家：
  孟加拉珠峰制药
- 适应症：
  KRAS抑制剂，肺癌新特药
索托拉西布基本信息
索托拉西布
- 剂型：
  片剂
- 厂家：
  老挝大熊制药
- 适应症：
  索托拉西布（Sotorasib）前称AMG 510，全球首个成药的KRAS G12C抑制剂，肺癌新特药
索托拉西布AMG510基本信息
索托拉西布AMG510
- 剂型：
  片剂
- 厂家：
  老挝大熊制药
- 适应症：
  索托拉西布（Sotorasib）前称AMG 510，全球首个成药的KRAS G12C抑制剂，肺癌新特药